• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

Chemical Profile of (1S)-2,2-dimethylcyclopropan-1-amine (CAS No. 106462-19-5)

The compound (1S)-2,2-dimethylcyclopropan-1-amine, identified by the CAS number 106462-19-5, is a significant molecule in the field of pharmaceutical chemistry and bioorganic synthesis. This chiral amine derivative belongs to the cyclopropane family, a structural motif known for its unique electronic and steric properties. The presence of the (1S) configuration indicates a specific stereochemical arrangement that can influence its reactivity and biological activity, making it a valuable candidate for further investigation in drug discovery and molecular design.

In recent years, there has been growing interest in cyclopropane-containing compounds due to their remarkable stability and ability to engage in diverse chemical transformations. The amine functional group in (1S)-2,2-dimethylcyclopropan-1-amine provides a versatile handle for further functionalization, enabling the synthesis of more complex derivatives with tailored properties. This flexibility has made it a useful intermediate in the development of novel pharmacophores targeting various therapeutic areas.

One of the most compelling aspects of this compound is its potential application in the synthesis of bioactive molecules. The cyclopropane ring is known to enhance binding affinity and metabolic stability, while the chiral center introduces specificity that is crucial for biological recognition. Recent studies have demonstrated that derivatives of this compound exhibit promising activity in preclinical models, particularly in the context of central nervous system (CNS) disorders and inflammatory conditions. The stereochemistry of the amine moiety plays a pivotal role in modulating pharmacological effects, with the (1S) configuration often showing enhanced efficacy compared to its enantiomer.

The synthesis of (1S)-2,2-dimethylcyclopropan-1-amine presents unique challenges due to the strained nature of the cyclopropane ring. However, advances in synthetic methodology have made it increasingly feasible to produce this compound with high enantioselectivity. One such approach involves asymmetric hydrogenation of appropriately substituted precursors, leveraging transition metal catalysts such as rhodium or palladium complexes coordinated with chiral ligands. These methods not only provide access to enantiomerically pure material but also offer insights into the mechanistic aspects of cyclopropane formation and functionalization.

In terms of biological activity, preliminary data suggest that (1S)-2,2-dimethylcyclopropan-1-amine and its derivatives may interact with specific protein targets involved in signal transduction pathways. For instance, some analogs have shown inhibitory effects on enzymes implicated in pain perception and neuroinflammation. The ability to fine-tune both the stereoelectronic properties and substituent patterns allows for the exploration of structure-activity relationships (SAR), which is essential for optimizing lead compounds into viable drug candidates.

The pharmaceutical industry has increasingly recognized the value of heterocyclic compounds like cyclopropanes in drug development. Their unique structural features contribute to favorable pharmacokinetic profiles, including improved solubility and reduced susceptibility to metabolic degradation. As such, there is significant interest in developing libraries of cyclopropane-based molecules for high-throughput screening (HTS) campaigns aimed at identifying novel therapeutic agents.

Furthermore, computational modeling has played an integral role in understanding the interactions between (1S)-2,2-dimethylcyclopropan-1-amine and biological targets. Molecular docking studies have helped elucidate binding modes and predict potential side effects, thereby accelerating the optimization process. These computational approaches are complemented by experimental validation using techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy to confirm structural hypotheses.

Looking ahead, future research directions may focus on exploring new synthetic routes to improve scalability and cost-efficiency. Additionally, there could be opportunities to expand the scope of derivatives by incorporating other functional groups or exploring different stereochemical configurations. Collaborative efforts between synthetic chemists and medicinal chemists will be crucial in translating these findings into tangible therapeutic benefits.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)